CompaniesSeneca Therapeutics

Seneca Therapeutics

active

Blue Bell, PA, United States

Founded 2020

About

Oncolytic immunotherapeutic

Areas of Focus

Categories

Biologics & BiopharmaceuticalVirus TechnologyVaccineNJ, NY, PA

Clinical Trials (1)

Total Trials

1

As Lead Sponsor

0

As Collaborator

1

Total Enrollment

36

By Phase

PHASE1: 1

By Status

RECRUITING: 1

Clinical Trials Pipeline1 trial

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2024

2025

2026

2027

2028

2029

2030

2031

Today

Hover over trial bars to see details

Recent Trials

NCT06889493Collaborator

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

PHASE1Recruiting

36 participants

Started: May 19, 2025 · Completed: Jun 1, 2030

Funding History (9)

D

Feb 7, 2025

D/A

Dec 23, 2022

D/A

Dec 22, 2021

D

Apr 2, 2021

D

Jun 23, 2020

D/A

Mar 19, 2020

D

Nov 22, 2019

D/A

Aug 8, 2019

D

May 30, 2019

Locations (1)

Headquarters

Blue Bell, PA, United States

Map

Loading map...